Browse TOB1

Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Only a small fraction localizes to the cytoplasm except in late S-phase where more than half of proteins become cytoplasmic.
Domain PF07742 BTG family
Function

Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex (PubMed:8632892, PubMed:23236473). Mediates CPEB3-accelerated mRNA deadenylation by binding to CPEB3 and recruiting CNOT7 which leads to target mRNA deadenylation and decay (PubMed:21336257).

> Gene Ontology
 
Biological Process GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006417 regulation of translation
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007184 SMAD protein import into nucleus
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010608 posttranscriptional regulation of gene expression
GO:0017038 protein import
GO:0017148 negative regulation of translation
GO:0019439 aromatic compound catabolic process
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030509 BMP signaling pathway
GO:0030510 regulation of BMP signaling pathway
GO:0030514 negative regulation of BMP signaling pathway
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034504 protein localization to nucleus
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044744 protein targeting to nucleus
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0046700 heterocycle catabolic process
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0060211 regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0060212 negative regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0060213 positive regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0061013 regulation of mRNA catabolic process
GO:0061014 positive regulation of mRNA catabolic process
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:1900151 regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1900152 negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1900153 positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1901361 organic cyclic compound catabolic process
GO:1902369 negative regulation of RNA catabolic process
GO:1902373 negative regulation of mRNA catabolic process
GO:1902593 single-organism nuclear import
GO:1903311 regulation of mRNA metabolic process
GO:1903312 negative regulation of mRNA metabolic process
GO:1903313 positive regulation of mRNA metabolic process
Molecular Function GO:0003714 transcription corepressor activity
GO:0005070 SH3/SH2 adaptor activity
GO:0030674 protein binding, bridging
GO:0030971 receptor tyrosine kinase binding
GO:0035591 signaling adaptor activity
GO:0046332 SMAD binding
GO:0060090 binding, bridging
GO:1990782 protein tyrosine kinase binding
Cellular Component GO:0030014 CCR4-NOT complex
> KEGG and Reactome Pathway
 
KEGG hsa03018 RNA degradation
Reactome -
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TOB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TOB1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TOB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6750.0273
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4430.826
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8460.564
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2530.534
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0580.979
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5040.862
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0150.968
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.070.962
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0240.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2570.86
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3690.867
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1170.402
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TOB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TOB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TOB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TOB1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TOB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TOB1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TOB1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTOB1
Nametransducer of ERBB2, 1
Aliases TOB; TROB; TROB1; APRO6; PIG49; proliferation-inducing gene 49; transducer of erbB-2 1; Protein Tob1
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TOB1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.